Lunai Bioworks (NASDAQ:LNAI – Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.44) EPS for the quarter, FiscalAI reports. The firm had revenue of $0.03 million during the quarter.
Lunai Bioworks Stock Performance
Shares of Lunai Bioworks stock opened at $1.03 on Wednesday. Lunai Bioworks has a 52-week low of $0.88 and a 52-week high of $13.28. The company’s 50 day moving average price is $2.05 and its 200-day moving average price is $2.52.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Lunai Bioworks in a report on Friday, October 2nd. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company currently has an average rating of “Sell”.
About Lunai Bioworks
Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.
Read More
- Five stocks we like better than Lunai Bioworks
- Tax Credit Turmoil: Why Enphase and SolarEdge Face a Tough Road
- A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
- Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
- Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
Receive News & Ratings for Lunai Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lunai Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
